DeepMed Research

LABORATOIRES THEA

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: -

Website: http://www.laboratoires-thea.com/

Clinical Trials

Extension Study to Study PQ-110-001 (NCT03140969)

Phase 1

Terminated

Conditions: Neurologic Manifestations
Eye Diseases, Hereditary
Retinal Disease
Blindness
Leber Congenital Amaurosis
Sensation Disorders
Vision Disorders
Eye Diseases
Eye Disorders Congenital
Leber Congenital Amaurosis 10

Interventions: Drug: QR-110

First Posted Date: 2019-04-12

Last Posted Date: 2024-10-15

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 9

Registration Number: NCT03913130

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇧🇪
Ghent University Hospital and Ghent University, Ghent, Belgium
🇺🇸
Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Efficacy of T2259 in DED

Not Applicable

Completed

Conditions: Dry Eye Syndromes

Interventions: Device: Vismed multi
Device: T2259

First Posted Date: 2019-03-14

Last Posted Date: 2023-11-01

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 101

Registration Number: NCT03874429

Locations: 🇫🇷
C.H.N.O des XV-XX, Paris, France

Efficacy, Safety of T2769 in Dry Eye Disease

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Other: T2769

First Posted Date: 2019-02-05

Last Posted Date: 2022-03-16

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 62

Registration Number: NCT03830359

Locations: 🇹🇳
Hôpital Universitaire Tahar Sfar, Mahdia, Tunisia
🇹🇳
"Hôpital Universitaire Fattouma Bourguiba, Monastir, Tunisia
🇹🇳
"Hôpital de Forces de Sécurité Intérieure La Marsa, Tunis, Tunisia

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost
Drug: Lumigan®

First Posted Date: 2019-01-31

Last Posted Date: 2023-11-21

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 485

Registration Number: NCT03825380

Locations: 🇪🇪
Hospital, Tallinn, Estonia

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Phase 1

Completed

Conditions: Leber's Congenital Amaurosis

Interventions: Drug: QR-110

First Posted Date: 2017-05-04

Last Posted Date: 2024-10-15

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 11

Registration Number: NCT03140969

Locations: 🇧🇪
Ghent University Hospital and Ghent University, Ghent, Belgium
🇺🇸
Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking

Not Applicable

Completed

Conditions: Keratoconus

Interventions: Device: T4020
Device: Placebo

First Posted Date: 2016-12-01

Last Posted Date: 2019-10-22

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 157

Registration Number: NCT02979054

Locations: 🇹🇷
Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Turkey
🇪🇸
Hospital, Vigo, Spain
🇫🇷
CHU, Clermont Ferrand, France

Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

Not Applicable

Terminated

Conditions: Dry Eye Syndrome

Interventions: Device: Optive
Device: T2762

First Posted Date: 2015-11-30

Last Posted Date: 2017-03-08

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 64

Registration Number: NCT02617095

Locations: 🇫🇷
Laboratoires Théa, Clermont-Ferrand, France

Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients

Phase 3

Completed

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: T2347
Drug: Xalacom

First Posted Date: 2014-10-30

Last Posted Date: 2017-04-28

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 242

Registration Number: NCT02278614

Locations: 🇫🇷
Laboratoires Thea, Clermont ferrand, France

Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Mydriatics
Drug: T2380
Drug: Tetracaine

First Posted Date: 2014-04-02

Last Posted Date: 2014-11-14

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 609

Registration Number: NCT02101359

Locations: 🇫🇷
Laboratoires Thea, Clermont- Ferrand, France

Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome

Phase 3

Completed

Conditions: Dry Eye Syndrome

Interventions: Device: Vismed®
Device: T2762

First Posted Date: 2013-12-30

Last Posted Date: 2017-08-24

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 105

Registration Number: NCT02023268

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy